Home > Journals > Minerva Gastroenterology > Past Issues > Articles online first > Minerva Gastroenterology 2021 Apr 15

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Minerva Gastroenterology 2021 Apr 15

DOI: 10.23736/S2724-5985.21.02835-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C

Marco SACCO, Giorgio M. SARACCO

Gastro-hepatoloy Unit, Department of Medical Sciences, University of Turin, Turin, Italy


PDF


BACKGROUND: there is robust epidemiological evidence suggesting the link of chronic Hepatitis C Virus (HCV) infection with type 2 diabetes mellitus (DM). Viral clearance achieved by Direct Acting Antiviral Agents (DAAs) has been associated to significant improvements in glycometabolic control but data on the long-term effect of Sustained Virological Response on diabetic disease are limited.
AIM: the aim of this review is to evaluate the influence of SVR after DAA-based therapy on Insulin Resistance (IR) and DM incidence in non-diabetic patients, on the glycemic homeostasis in diabetic patients and on their long-term hepatic and metabolic outcomes.
METHODS: an electronic search of Embase, PubMed, MEDLINE, Ovid and the Cochrane Database of Systematic Reviews was performed for papers regarding the effect of DAAinduced SVR on the glycometabolic control and clinical outcomes of HCV-positive diabetic patients up to September 30, 2020.
RESULTS: among non-diabetic patients, a significant reduction in the risk of IR and DM was reported by the vast majority of the studies; the glycometabolic control significantly improved in diabetic patients during and immediately after the end of antiviral treatment. However, whether this beneficial effect is long lasting is still matter of debate. Furthermore, at variance with data obtained during the Interferon (IFN) era, DM does not seem to be an unfavourable predictive factor of Hepatocellular Carcinoma (HCC) in cured patients.
CONCLUSIONS: a favourable influence of DAA-induced SVR on IR and DM incidence and on glycemic control is reported by several studies. However, the long-term biochemical, metabolic and clinical impact of this endocrine benefit remains largely unknown.


KEY WORDS: Hepatitis C Virus; Chronic hepatitis C; Insulin resistance; Diabetes mellitus; Impaired fasting glucose; Direct acting antiviral agents; Cirrhosis; Anti-diabetic therapy

top of page